PYGL and head and neck squamous cell carcinoma: As Fig. 5D and E revealed, xenograft derived from PYGL knock-down cell lines was significantly diminished compared with the control, and cisplatin’s inhibition to HNSCC was also amplified at PYGL knock-down group.